- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Hari on the Role of MRD in Multiple Myeloma
June 12th 2020, 9:22pm
European Hematology Association Congress
Parameswaran Hari, MD, MRCP, discusses the role of minimal residual disease in multiple myeloma.
Dr. Costa on Safety of CC-93269 in Relapsed/Refractory Myeloma
June 12th 2020, 9:12pm
European Hematology Association Congress
Luciano J. Costa, MD, PhD, discusses the safety results of CC-93269 in patients with relapsed/refractory multiple myeloma.
Serum Biomarkers Are Early Predictors for Haplo-SCT Outcomes
June 12th 2020, 7:05pm
European Hematology Association Congress
Higher levels of the serum biomarkers ST2 and REG3α were associated with increased incidence of graft-vs-host disease and increased risk for transplant-related mortality in patients who have undergone haploidentical stem-cell transplantation with post-transplant cyclophosphamide.
Pegcetacoplan Outperforms Current Standard of Care in Paroxysmal Nocturnal Hemoglobinuria
June 12th 2020, 6:30am
European Hematology Association Congress
The novel C3 inhibitor pegcetacoplan led to a significant improvement in hemoglobin level and other clinical outcomes at week 16 versus the current standard of care, eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
Ruxolitinib Improves Outcomes in aGVHD Across Subgroups
June 12th 2020, 6:30am
European Hematology Association Congress
Ruxolitinib (Jakafi) induced a strong, durable response across several subgroups of patients with steroid-refractory acute graft-versus-host disease.
Ibrutinib/Venetoclax Triplet Demonstrates Frontline Activity in High-Risk CLL
June 12th 2020, 6:30am
European Hematology Association Congress
The triplet regimen of ibrutinib, venetoclax, and obinutuzumab demonstrated encouraging response rates with an acceptable safety profile in treatment-naïve patients with high-risk chronic lymphocytic leukemia.
Imetelstat Provides Promising, Durable Transfusion Independence in Lower-Risk MDS
June 12th 2020, 6:30am
European Hematology Association Congress
Imetelstat demonstrated meaningful and durable transfusion independence in patients with lower-risk myelodysplastic syndrome that are non-del(5q), dependent on red blood cell transfusion, and are relapsed/refractory to treatment with erythropoiesis-stimulating agents.
Omitting Radiation Does Not Reduce Survival for Patients with Early Unfavorable HL
June 12th 2020, 6:30am
European Hematology Association Congress
Radiation therapy can be omitted in patients with newly diagnosed early-stage unfavorable Hodgkin lymphoma without sacrificing efficacy.
Dr. Usmani on Activity of Teclistamab in Relapsed/Refractory Multiple Myeloma
June 1st 2020, 2:04am
Saad Usmani, MD, discusses research with teclistamab (JNJ-64007957) in relapsed/refractory multiple myeloma presented at the 2020 ASCO Virtual Scientific Program.
Alectinib Continues to Maintain Significant OS Benefit in ALK+ NSCLC
June 1st 2020, 12:02am
The highly selective second-generation TKI alectinib demonstrated a clinically meaningful improvement in overall survival compared with crizotinib in patients with ALK-positive non–small cell lung cancer.
Tepotinib Displays Durable Clinical Benefit in METex14-Altered NSCLC
May 31st 2020, 11:07pm
The oral, highly selective MET inhibitor tepotinib demonstrated durable clinical activity in patients with locally advanced or metastatic non–small cell lung cancer who harbor a MET exon 14 skipping mutation identified through liquid or tissue biopsy.
Robust Data and Multivariate Analyses Support Cabazitaxel as a Standard of Care in mCRPC
May 31st 2020, 10:57pm
The use of cabazitaxel over abiraterone acetate or enzalutamide may continue as a standard of care in men with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and either of those 2 androgen receptor-targeted agents.
Cabozantinib Plus Atezolizumab Shows Promise in mCRPC
May 31st 2020, 10:39pm
The combination of cabozantinib and atezolizumab showed clinically meaningful activity in patients with metastatic castration-resistant prostate cancer.
Darolutamide Improves OS, Delays Onset of Cancer-Related Morbidity and Subsequent Chemo in Nonmetastatic CRPC
May 31st 2020, 10:05pm
Darolutamide (Nubeqa) plus androgen deprivation therapy led to a 31% reduction in the risk of death compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer.
IMvigor010 Misses DFS End Point in Muscle-Invasive Urothelial Carcinoma
May 31st 2020, 8:58pm
The phase 3 IMvigor010 trial comparing adjuvant atezolizumab with observation in patients with muscle-invasive urothelial carcinoma failed to meet its primary endpoint of disease-free survival.
Cabozantinib Maintains Efficacy in Advanced RCC Irrespective of Prior Treatment
May 31st 2020, 5:52pm
Patients with advanced renal cell carcinoma who were treated with cabozantinib (Cabometyx) following both immunotherapy and non-IO regimens demonstrated promising responses.
Pyrotinib Combo Improves PFS in HER2+ Metastatic Breast Cancer
May 31st 2020, 5:31pm
Pyrotinib plus capecitabine achieved a better progression-free survival than lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and chemotherapy.
Longer Follow-Up for Cemiplimab Confirms Superior Efficacy Over Other Regimens for CSCC
May 31st 2020, 5:22pm
In the phase 2 trial EMPOWER-CSCC-1, up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response for cemiplimab-rwlc in patients with advanced cutaneous squamous cell carcinoma.
Baseline and Posttreatment ctDNA Positivity Linked to Poor Prognosis, rPFS in mCRPC
May 31st 2020, 5:18pm
Baseline and posttreatment circulating tumor DNA positivity was associated with worse radiologic progression-free survival in patients with metastatic castration-resistant prostate cancer.
Frontline Pembrolizumab/Axitinib Survival Benefit Upholds in Advanced RCC
May 31st 2020, 3:32am
The combination of pembrolizumab and axitinib continued to demonstrate a clinically significant improvement in progression-free and overall survival compared with sunitinib in patients with previously untreated, advanced renal cell carcinoma.